Charles River Laboratories International Inc. Stock Climbs 7.8%, Outperforms Peers
Dow Jones2026/11/06 21:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Charles River Laboratories International Inc. advanced 7.8% to $337.52 on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.3% to 7,376.86 and the Dow Jones Industrial Average falling 0.5% to 51,285.73.
The stock's rise snapped a two-day losing streak.
Charles River Laboratories International Inc. closed 11.1% short of its 52-week high of $379.63, which the company reached on October 29th.
The stock outperformed some of its peers, as Labcorp Holdings Inc. rose 0.9% to $366.57, Alnylam Pharmaceuticals Inc. fell 0.5% to $155.94, and Bio-Techne Corp. rose 0.17% to $72.78.
Trading volume totaled 982,830, compared to the 50-day average of 1.1 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
November 06, 2026 16:34 ET (21:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
